Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyEnalaprilat
Identification
- Name
- Enalaprilat
- Accession Number
- DB09477
- Type
- Small Molecule
- Groups
- Approved
- Description
Enalaprilat is the active metabolite of the orally available pro-drug, enalapril. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume. Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth. Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.
Enalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible.
- Structure
Structure for DB09477 (Enalaprilat)
- Synonyms
- Enalaprilat anhydrous
- Product Ingredients
Ingredient UNII CAS InChI Key Enalaprilat dihydrate GV0O7ES0R3 84680-54-6 MZYVOFLIPYDBGD-MLZQUWKJSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Enalaprilat Injection USP Solution 1.25 mg Intravenous Sterimax Inc 2012-09-10 Not applicable Canada 
Vasotec IV Solution 1.25 mg Intravenous Sandoz Canada Incorporated 1992-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Enalaprilat Injection 2.5 mg/2mL Intravenous West Ward Pharmaceutical 2008-12-23 Not applicable US 
Enalaprilat Injection, solution 1.25 mg/mL Intravenous Teva Parenteral Medicines, Inc. 2005-10-06 Not applicable US Enalaprilat Injection 1.25 mg/mL Intravenous West Ward Pharmaceutical 2008-12-23 Not applicable US Enalaprilat Injection 1.25 mg/mL Intravenous Cardinal Health 2000-08-23 Not applicable US Enalaprilat Injection, solution 1.25 mg/mL Intravenous Teva Parenteral Medicines, Inc. 2005-10-06 Not applicable US Enalaprilat Injection, solution 1.25 mg/mL Intravenous Hospira, Inc. 2000-08-22 Not applicable US - Categories
- UNII
- Q508Q118JM
- CAS number
- 76420-72-9
- Weight
- Average: 348.3936
Monoisotopic: 348.168521888 - Chemical Formula
- C18H24N2O5
- InChI Key
- LZFZMUMEGBBDTC-QEJZJMRPSA-N
- InChI
- InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
- IUPAC Name
- (2S)-1-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]pyrrolidine-2-carboxylic acid
- SMILES
- [H][[email protected]@](C)(N[[email protected]@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[[email protected]@]1([H])C(O)=O
Pharmacology
- Indication
Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical.
- Structured Indications
- Pharmacodynamics
Enalaprilat injection results in the reduction of both supine and standing systolic and diastolic blood pressure, usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients. The onset of action usually occurs within fifteen minutes of administration with the maximum effect occurring within one to four hours. The abrupt withdrawal of enalaprilat has not been associated with a rapid increase in blood pressure. The duration of hemodynamic effects appears to be dose-related. However, for the recommended dose, the duration of action in most patients is approximately six hours. Following administration of enalapril, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension.
- Mechanism of action
Enalaprilat is the active metabolite of the orally available pro-drug, enalapril. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume
Target Actions Organism AAngiotensin-converting enzyme inhibitorHuman UB1 bradykinin receptor Not Available Human - Absorption
Enalaprilat is poorly absorbed following oral administration, and is therefore only available as an intravenous injection.
- Volume of distribution
- Not Available
- Protein binding
Enalaprilat is approximately 50% bound to plasma proteins. (Davies, et al. 1984)
- Metabolism
Both enalapril and enalaprilat undergo renal excretion without further metabolism.
- Route of elimination
Excretion of enalaprilat is primarily renal with more than 90 percent of an administered dose recovered in the urine as unchanged drug within 24 hours.
- Half life
11 hr
- Clearance
The disposition of enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. Renal clearance was 158 ± 47 ml/min.
- Toxicity
Adverse experiences occurring in 0.5 to 1.0 percent of patients in controlled clinical trials included: myocardial infarction, fatigue, dizziness, fever, rash and constipation. Angioedema has also been reported in patients receiving enalaprilat, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalaprilat should be discontinued and appropriate therapy instituted immediately .
Rarer adverse effects that are less likely, but should be monitored for, include development of anaphylaxis, hypotension, agranulocytosis, hepatic failure, hyperkalemia, and persistent cough.
Furthermore, ACE inhibitors should be avoided during pregnancy as they can cause fetal and neonatal morbidity and death. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. Use during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Enalaprilat. Experimental Abacavir The serum concentration of Abacavir can be decreased when it is combined with Enalaprilat. Approved, Investigational Acebutolol Acebutolol may increase the hypotensive activities of Enalaprilat. Approved Aceclofenac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Aceclofenac. Approved Acemetacin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Acemetacin. Approved Acetylsalicylic acid Acetylsalicylic acid may decrease the antihypertensive activities of Enalaprilat. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Enalaprilat is combined with Adapalene. Approved Alclofenac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Alclofenac. Approved, Withdrawn Aldesleukin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Aldesleukin. Approved Alfuzosin Alfuzosin may increase the hypotensive activities of Enalaprilat. Approved, Investigational Aliskiren Aliskiren may increase the hyperkalemic activities of Enalaprilat. Approved, Investigational Allopurinol The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Enalaprilat. Approved Alminoprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Alminoprofen. Experimental Alogliptin The risk or severity of adverse effects can be increased when Alogliptin is combined with Enalaprilat. Approved Aloxiprin Aloxiprin may decrease the antihypertensive activities of Enalaprilat. Experimental Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Enalaprilat. Approved, Illicit, Investigational Alprenolol Alprenolol may increase the hypotensive activities of Enalaprilat. Approved, Withdrawn Ambrisentan Enalaprilat may increase the hypotensive activities of Ambrisentan. Approved, Investigational Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Enalaprilat. Experimental Amifostine Enalaprilat may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride Amiloride may increase the hyperkalemic activities of Enalaprilat. Approved Amineptine The serum concentration of Amineptine can be increased when it is combined with Enalaprilat. Illicit, Withdrawn Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Enalaprilat. Approved Aminosalicylic Acid Aminosalicylic Acid may decrease the antihypertensive activities of Enalaprilat. Approved Amiodarone The risk or severity of adverse effects can be increased when Amiodarone is combined with Enalaprilat. Approved, Investigational Amitriptyline The serum concentration of Amitriptyline can be increased when it is combined with Enalaprilat. Approved Amlodipine Amlodipine may increase the hypotensive activities of Enalaprilat. Approved Amobarbital Amobarbital may increase the hypotensive activities of Enalaprilat. Approved, Illicit Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Enalaprilat. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Enalaprilat is combined with Amyl Nitrite. Approved Andrographolide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Andrographolide. Investigational Anisodamine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Anisodamine. Investigational Antipyrine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Antipyrine. Approved Apocynin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Apocynin. Investigational Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Enalaprilat. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Apraclonidine. Approved Apremilast The risk or severity of adverse effects can be increased when Enalaprilat is combined with Apremilast. Approved, Investigational Aprotinin Aprotinin may decrease the antihypertensive activities of Enalaprilat. Approved, Withdrawn Ardeparin Ardeparin may increase the hyperkalemic activities of Enalaprilat. Approved, Withdrawn Aripiprazole Aripiprazole may increase the hypotensive activities of Enalaprilat. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Enalaprilat. Approved Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Enalaprilat. Approved, Investigational Atenolol Atenolol may increase the hypotensive activities of Enalaprilat. Approved Atorvastatin The serum concentration of Atorvastatin can be increased when it is combined with Enalaprilat. Approved Azapropazone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Azapropazone. Withdrawn Azathioprine Enalaprilat may increase the myelosuppressive activities of Azathioprine. Approved Azelastine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Azelastine. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Enalaprilat. Approved Balsalazide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Balsalazide. Approved, Investigational Barbexaclone Barbexaclone may increase the hypotensive activities of Enalaprilat. Experimental Barbital Barbital may increase the hypotensive activities of Enalaprilat. Illicit Barnidipine The risk or severity of adverse effects can be increased when Barnidipine is combined with Enalaprilat. Approved Bemiparin Bemiparin may increase the hyperkalemic activities of Enalaprilat. Approved Benazepril Benazepril may increase the hypotensive activities of Enalaprilat. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Bendazac. Experimental Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Enalaprilat. Approved Benmoxin Benmoxin may increase the hypotensive activities of Enalaprilat. Withdrawn Benorilate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Benoxaprofen. Withdrawn Bepridil Bepridil may increase the hypotensive activities of Enalaprilat. Approved, Withdrawn Betaxolol Betaxolol may increase the hypotensive activities of Enalaprilat. Approved Bethanidine Bethanidine may increase the hypotensive activities of Enalaprilat. Approved Bevonium The risk or severity of adverse effects can be increased when Enalaprilat is combined with Bevonium. Experimental Bietaserpine Bietaserpine may increase the hypotensive activities of Enalaprilat. Experimental Bimatoprost Bimatoprost may increase the hypotensive activities of Enalaprilat. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Enalaprilat. Approved Boceprevir The serum concentration of Enalaprilat can be decreased when it is combined with Boceprevir. Withdrawn Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Enalaprilat. Approved, Investigational Bosentan Bosentan may increase the hypotensive activities of Enalaprilat. Approved, Investigational BQ-123 Enalaprilat may increase the hypotensive activities of BQ-123. Investigational Bretylium Bretylium may increase the hypotensive activities of Enalaprilat. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Enalaprilat. Approved Brofaromine Brofaromine may increase the hypotensive activities of Enalaprilat. Experimental Bromfenac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Bromfenac. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Enalaprilat. Approved, Investigational Bucillamine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Bucillamine. Investigational Bufexamac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Bufexamac. Experimental Bumadizone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Bumadizone. Experimental Bumetanide Bumetanide may increase the hypotensive activities of Enalaprilat. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Enalaprilat. Approved, Investigational Bupranolol Bupranolol may increase the hypotensive activities of Enalaprilat. Approved Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Enalaprilat. Approved Cadralazine Cadralazine may increase the hypotensive activities of Enalaprilat. Experimental Cafedrine Enalaprilat may increase the hypotensive activities of Cafedrine. Investigational Canagliflozin Canagliflozin may increase the hyperkalemic activities of Enalaprilat. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Enalaprilat. Approved Candoxatril Candoxatril may increase the hypotensive activities of Enalaprilat. Experimental Captopril Captopril may increase the hypotensive activities of Enalaprilat. Approved Carbamazepine The metabolism of Enalaprilat can be increased when combined with Carbamazepine. Approved, Investigational Carbaspirin calcium Carbaspirin calcium may decrease the antihypertensive activities of Enalaprilat. Experimental Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Enalaprilat. Approved Caroxazone Caroxazone may increase the hypotensive activities of Enalaprilat. Withdrawn Carprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Carprofen. Approved, Vet Approved, Withdrawn Carteolol Carteolol may increase the hypotensive activities of Enalaprilat. Approved Carvedilol Carvedilol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Castanospermine. Experimental Celecoxib The risk or severity of adverse effects can be increased when Enalaprilat is combined with Celecoxib. Approved, Investigational Celiprolol Celiprolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Certoparin Certoparin may increase the hyperkalemic activities of Enalaprilat. Approved Chloroquine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Chloroquine. Approved, Vet Approved Chlorothiazide Chlorothiazide may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Chlorotrianisene The serum concentration of Chlorotrianisene can be decreased when it is combined with Enalaprilat. Withdrawn Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enalaprilat. Approved, Vet Approved Chlorthalidone Chlorthalidone may increase the hypotensive activities of Enalaprilat. Approved Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Choline magnesium trisalicylate. Approved Cicletanine Enalaprilat may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Cilazapril may increase the hypotensive activities of Enalaprilat. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Enalaprilat. Approved Ciprofloxacin Enalaprilat may increase the arrhythmogenic activities of Ciprofloxacin. Approved, Investigational Cisapride The serum concentration of Cisapride can be increased when it is combined with Enalaprilat. Approved, Investigational, Withdrawn Clarithromycin The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalaprilat. Approved Clevidipine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Clevidipine. Approved Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Enalaprilat. Approved, Investigational Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Enalaprilat. Approved, Vet Approved Clonidine Clonidine may increase the hypotensive activities of Enalaprilat. Approved Clonixin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Clonixin. Approved Cloranolol Enalaprilat may increase the hypotensive activities of Cloranolol. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Enalaprilat. Approved Conivaptan The risk or severity of adverse effects can be increased when Conivaptan is combined with Enalaprilat. Approved, Investigational Conjugated estrogens The serum concentration of Conjugated estrogens can be decreased when it is combined with Enalaprilat. Approved Cryptenamine Cryptenamine may increase the hypotensive activities of Enalaprilat. Approved Curcumin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Curcumin. Investigational Cyclobenzaprine The serum concentration of Cyclobenzaprine can be increased when it is combined with Enalaprilat. Approved Cyclopenthiazide Enalaprilat may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclophosphamide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Cyclophosphamide. Approved, Investigational Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Enalaprilat. Approved, Investigational, Vet Approved Cyclothiazide Cyclothiazide may increase the hypotensive activities of Enalaprilat. Approved D-Limonene The risk or severity of adverse effects can be increased when Enalaprilat is combined with D-Limonene. Investigational Dalteparin Dalteparin may increase the hyperkalemic activities of Enalaprilat. Approved Dapagliflozin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dapagliflozin. Approved Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Enalaprilat. Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Enalaprilat. Approved Delapril Enalaprilat may increase the hypotensive activities of Delapril. Experimental Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Enalaprilat. Approved dersalazine dersalazine may decrease the antihypertensive activities of Enalaprilat. Investigational Deserpidine Enalaprilat may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Enalaprilat. Approved Desipramine The serum concentration of Desipramine can be increased when it is combined with Enalaprilat. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dexmedetomidine. Approved, Vet Approved Diazoxide Diazoxide may increase the hypotensive activities of Enalaprilat. Approved Dibenzepin The serum concentration of Dibenzepin can be increased when it is combined with Enalaprilat. Experimental Diclofenac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Diclofenac. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Diclofenamide. Approved Dienestrol The serum concentration of Dienestrol can be decreased when it is combined with Enalaprilat. Approved diethylnorspermine diethylnorspermine may increase the hypotensive activities of Enalaprilat. Investigational Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalaprilat. Approved Difenpiramide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Difenpiramide. Experimental Diflunisal Diflunisal may decrease the antihypertensive activities of Enalaprilat. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Enalaprilat. Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Enalaprilat. Investigational Dihydroergotamine The serum concentration of Dihydroergotamine can be increased when it is combined with Enalaprilat. Approved Diltiazem The metabolism of Diltiazem can be decreased when combined with Enalaprilat. Approved Dinutuximab The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dinutuximab. Approved Dipyridamole The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dipyridamole. Approved Dorzolamide Dorzolamide may increase the hypotensive activities of Enalaprilat. Approved Dosulepin The serum concentration of Dosulepin can be increased when it is combined with Enalaprilat. Approved Doxazosin Doxazosin may increase the hypotensive activities of Enalaprilat. Approved Doxepin The serum concentration of Doxepin can be increased when it is combined with Enalaprilat. Approved Drospirenone Enalaprilat may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Enalaprilat is combined with Droxicam. Approved Duloxetine Enalaprilat may increase the orthostatic hypotensive activities of Duloxetine. Approved Duvelisib The risk or severity of adverse effects can be increased when Enalaprilat is combined with Duvelisib. Investigational Dyphylline The serum concentration of Dyphylline can be decreased when it is combined with Enalaprilat. Approved E-6201 The risk or severity of adverse effects can be increased when Enalaprilat is combined with E-6201. Investigational Efonidipine Efonidipine may increase the hypotensive activities of Enalaprilat. Approved Empagliflozin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Empagliflozin. Approved Enalapril Enalapril may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Endralazine Endralazine may increase the hypotensive activities of Enalaprilat. Experimental Enfuvirtide The serum concentration of Enfuvirtide can be increased when it is combined with Enalaprilat. Approved, Investigational Enoxaparin Enoxaparin may increase the hyperkalemic activities of Enalaprilat. Approved Epanolol Enalaprilat may increase the hypotensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Enalaprilat is combined with Epirizole. Approved Eplerenone Eplerenone may increase the hyperkalemic activities of Enalaprilat. Approved Epoprostenol Epoprostenol may increase the hypotensive activities of Enalaprilat. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Enalaprilat. Approved Ergoloid mesylate The serum concentration of Ergoloid mesylate can be increased when it is combined with Enalaprilat. Approved Ergonovine The serum concentration of Ergonovine can be increased when it is combined with Enalaprilat. Approved Ergotamine The serum concentration of Ergotamine can be increased when it is combined with Enalaprilat. Approved Esmirtazapine The serum concentration of Esmirtazapine can be increased when it is combined with Enalaprilat. Investigational Esmolol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Esmolol. Approved Estradiol The serum concentration of Estradiol can be decreased when it is combined with Enalaprilat. Approved, Investigational, Vet Approved Estramustine The serum concentration of Estramustine can be decreased when it is combined with Enalaprilat. Approved Estrogens, esterified The serum concentration of Estrogens, esterified can be decreased when it is combined with Enalaprilat. Approved Estrone sulfate The serum concentration of Estrone sulfate can be decreased when it is combined with Enalaprilat. Approved Etacrynic acid Etacrynic acid may increase the hypotensive activities of Enalaprilat. Approved Etanercept The risk or severity of adverse effects can be increased when Enalaprilat is combined with Etanercept. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ethenzamide. Experimental Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalaprilat. Approved Etodolac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Etofenamate. Approved Etoricoxib The risk or severity of adverse effects can be increased when Enalaprilat is combined with Etoricoxib. Approved, Investigational Etravirine The serum concentration of Etravirine can be decreased when it is combined with Enalaprilat. Approved Evening primrose oil The risk or severity of adverse effects can be increased when Enalaprilat is combined with Evening primrose oil. Approved Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Enalaprilat. Approved exisulind The risk or severity of adverse effects can be increased when Enalaprilat is combined with exisulind. Investigational Felbinac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Felbinac. Experimental Felodipine Felodipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Fenbufen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Fenbufen. Approved Fenoldopam Fenoldopam may increase the hypotensive activities of Enalaprilat. Approved Fenoprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Fenoprofen. Approved Fentiazac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Feprazone. Experimental Ferulic acid Ferulic acid may increase the hypotensive activities of Enalaprilat. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Enalaprilat. Approved Floctafenine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Floctafenine. Approved, Withdrawn Flunixin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Flunixin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Flunoxaprofen. Experimental Flurbiprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Flurbiprofen. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Enalaprilat. Experimental Fosinopril Fosinopril may increase the hypotensive activities of Enalaprilat. Approved Furazolidone Furazolidone may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Furosemide Furosemide may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Garlic The serum concentration of Enalaprilat can be decreased when it is combined with Garlic. Approved Guacetisal Guacetisal may decrease the antihypertensive activities of Enalaprilat. Experimental Guanabenz Guanabenz may increase the hypotensive activities of Enalaprilat. Approved Guanadrel Guanadrel may increase the hypotensive activities of Enalaprilat. Approved Guanazodine Enalaprilat may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Guanethidine may increase the hypotensive activities of Enalaprilat. Approved Guanfacine Guanfacine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Guanoclor Enalaprilat may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Enalaprilat may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Enalaprilat may increase the hypotensive activities of Guanoxan. Experimental Halothane The risk or severity of adverse effects can be increased when Enalaprilat is combined with Halothane. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Enalaprilat. Experimental Hemoglobin crosfumaril Hemoglobin crosfumaril may decrease the antihypertensive activities of Enalaprilat. Experimental Heparin Heparin may increase the hyperkalemic activities of Enalaprilat. Approved, Investigational Hexamethonium Hexamethonium may increase the hypotensive activities of Enalaprilat. Experimental Hexestrol The serum concentration of Hexestrol can be decreased when it is combined with Enalaprilat. Withdrawn Hexobarbital Hexobarbital may increase the hypotensive activities of Enalaprilat. Approved Higenamine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Higenamine. Investigational Hydracarbazine Hydracarbazine may increase the hypotensive activities of Enalaprilat. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Enalaprilat. Approved Hydrochlorothiazide Hydrochlorothiazide may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may increase the hypotensive activities of Enalaprilat. Approved Ibuprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ibuprofen. Approved Ibuproxam The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ibuproxam. Withdrawn Icatibant Icatibant may decrease the antihypertensive activities of Enalaprilat. Approved Iloprost Iloprost may increase the hypotensive activities of Enalaprilat. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Enalaprilat is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Imidazole salicylate. Experimental Imipramine The serum concentration of Imipramine can be increased when it is combined with Enalaprilat. Approved Indapamide Indapamide may increase the hypotensive activities of Enalaprilat. Approved Indenolol Indenolol may increase the hypotensive activities of Enalaprilat. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Indomethacin. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Indoprofen. Withdrawn Indoramin Indoramin may increase the hypotensive activities of Enalaprilat. Withdrawn Iprindole The serum concentration of Iprindole can be increased when it is combined with Enalaprilat. Experimental Iproclozide Iproclozide may increase the hypotensive activities of Enalaprilat. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Enalaprilat. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Enalaprilat. Approved, Investigational Iron The risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron. Approved Iron Dextran The risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron Dextran. Approved, Vet Approved Isocarboxazid Isocarboxazid may increase the hypotensive activities of Enalaprilat. Approved Isoflurane The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoflurane. Approved, Vet Approved Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Dinitrate. Approved Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Mononitrate. Approved Isoxicam The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoxicam. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoxsuprine. Approved, Withdrawn Isradipine Isradipine may increase the hypotensive activities of Enalaprilat. Approved Kebuzone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Kebuzone. Experimental Ketanserin Ketanserin may increase the hypotensive activities of Enalaprilat. Investigational Ketoprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ketoprofen. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ketorolac. Approved Labetalol Labetalol may increase the hypotensive activities of Enalaprilat. Approved Lacidipine Lacidipine may increase the hypotensive activities of Enalaprilat. Approved Lanthanum carbonate The serum concentration of Enalaprilat can be decreased when it is combined with Lanthanum carbonate. Approved Latanoprost Latanoprost may increase the hypotensive activities of Enalaprilat. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Leflunomide. Approved, Investigational Lercanidipine Lercanidipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Levobupivacaine. Approved Levodopa Enalaprilat may increase the orthostatic hypotensive activities of Levodopa. Approved Levosimendan The risk or severity of adverse effects can be increased when Enalaprilat is combined with Levosimendan. Approved, Investigational Linagliptin The risk or severity of adverse effects can be increased when Linagliptin is combined with Enalaprilat. Approved Linsidomine Enalaprilat may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Lisinopril may increase the hypotensive activities of Enalaprilat. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Enalaprilat is combined with Lisofylline. Investigational Lithium The serum concentration of Lithium can be increased when it is combined with Enalaprilat. Approved Lofepramine The serum concentration of Lofepramine can be increased when it is combined with Enalaprilat. Experimental Lofexidine Lofexidine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Enalaprilat is combined with Lornoxicam. Approved Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Enalaprilat. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Enalaprilat. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Loxoprofen. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Enalaprilat is combined with Lumiracoxib. Approved, Investigational Macitentan Enalaprilat may increase the hypotensive activities of Macitentan. Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Magnesium salicylate. Approved Manidipine Manidipine may increase the hypotensive activities of Enalaprilat. Approved Mannitol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Mannitol. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Masoprocol. Approved Mebanazine Mebanazine may increase the hypotensive activities of Enalaprilat. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Enalaprilat. Approved Meclofenamic acid The risk or severity of adverse effects can be increased when Enalaprilat is combined with Meclofenamic acid. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Enalaprilat is combined with Mefenamic acid. Approved Meloxicam The risk or severity of adverse effects can be increased when Enalaprilat is combined with Meloxicam. Approved, Vet Approved Mesalazine Mesalazine may decrease the antihypertensive activities of Enalaprilat. Approved Mestranol The serum concentration of Mestranol can be decreased when it is combined with Enalaprilat. Approved Metamizole The risk or severity of adverse effects can be increased when Enalaprilat is combined with Metamizole. Withdrawn Methallenestril The serum concentration of Methallenestril can be decreased when it is combined with Enalaprilat. Experimental Methazolamide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Methazolamide. Approved Methohexital Methohexital may increase the hypotensive activities of Enalaprilat. Approved Methoserpidine Enalaprilat may increase the hypotensive activities of Methoserpidine. Experimental Methyclothiazide Methyclothiazide may increase the hypotensive activities of Enalaprilat. Approved Methyldopa Methyldopa may increase the hypotensive activities of Enalaprilat. Approved Methylene blue Methylene blue may increase the hypotensive activities of Enalaprilat. Investigational Methylergometrine The serum concentration of Methylergometrine can be increased when it is combined with Enalaprilat. Approved Methylphenidate Methylphenidate may decrease the antihypertensive activities of Enalaprilat. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the hypotensive activities of Enalaprilat. Approved Metipranolol Metipranolol may increase the hypotensive activities of Enalaprilat. Approved Metolazone Metolazone may increase the hypotensive activities of Enalaprilat. Approved Metoprolol Metoprolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Metyrosine Enalaprilat may increase the hypotensive activities of Metyrosine. Approved Mibefradil Mibefradil may increase the hypotensive activities of Enalaprilat. Withdrawn Midazolam The serum concentration of Midazolam can be increased when it is combined with Enalaprilat. Approved, Illicit Minaprine Minaprine may increase the hypotensive activities of Enalaprilat. Approved Minoxidil Minoxidil may increase the hypotensive activities of Enalaprilat. Approved Mirodenafil Mirodenafil may increase the antihypertensive activities of Enalaprilat. Investigational Mirtazapine The serum concentration of Mirtazapine can be increased when it is combined with Enalaprilat. Approved Mizoribine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Mizoribine. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Enalaprilat. Approved Moexipril Moexipril may increase the hypotensive activities of Enalaprilat. Approved Mofebutazone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Mofebutazone. Experimental Molsidomine Molsidomine may increase the hypotensive activities of Enalaprilat. Approved Morphine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Morphine. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Enalaprilat. Approved Muzolimine Enalaprilat may increase the hypotensive activities of Muzolimine. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolate mofetil. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolic acid. Approved Nabilone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nabilone. Approved, Investigational Nabumetone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nabumetone. Approved Nadolol Nadolol may increase the hypotensive activities of Enalaprilat. Approved Nadroparin Nadroparin may increase the hyperkalemic activities of Enalaprilat. Approved Nafamostat The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Naftifine. Approved Naftopidil Enalaprilat may increase the hypotensive activities of Naftopidil. Investigational Naproxen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Naproxen. Approved, Vet Approved Nebivolol Nebivolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Nefazodone The serum concentration of Nefazodone can be increased when it is combined with Enalaprilat. Approved, Withdrawn Nepafenac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nepafenac. Approved Nesiritide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nesiritide. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Enalaprilat. Withdrawn Nicardipine Nicardipine may increase the hypotensive activities of Enalaprilat. Approved Nicorandil Nicorandil may increase the hyperkalemic activities of Enalaprilat. Approved Nifedipine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nifedipine. Approved Nifenazone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Enalaprilat is combined with Niflumic Acid. Approved Niguldipine Niguldipine may increase the hypotensive activities of Enalaprilat. Experimental Nilvadipine Nilvadipine may increase the hypotensive activities of Enalaprilat. Approved Nimesulide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nimesulide. Approved, Withdrawn Nimodipine Nimodipine may increase the hypotensive activities of Enalaprilat. Approved Nisoldipine Nisoldipine may increase the hypotensive activities of Enalaprilat. Approved Nitrendipine Nitrendipine may increase the hypotensive activities of Enalaprilat. Approved Nitric Oxide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitric Oxide. Approved Nitroaspirin Nitroaspirin may decrease the antihypertensive activities of Enalaprilat. Investigational Nitroglycerin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Enalaprilat. Approved Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Enalaprilat. Approved Obinutuzumab Enalaprilat may increase the hypotensive activities of Obinutuzumab. Approved Octamoxin Octamoxin may increase the hypotensive activities of Enalaprilat. Withdrawn Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Enalaprilat. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Olopatadine. Approved Olsalazine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Olsalazine. Approved Omapatrilat Omapatrilat may increase the hypotensive activities of Enalaprilat. Investigational Opipramol The serum concentration of Opipramol can be increased when it is combined with Enalaprilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Enalaprilat is combined with Orgotein. Vet Approved Oxaprozin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Oxaprozin. Approved Oxprenolol Oxprenolol may increase the hypotensive activities of Enalaprilat. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Oxyphenbutazone. Withdrawn Paclitaxel The risk or severity of adverse effects can be increased when Enalaprilat is combined with Paclitaxel. Approved, Vet Approved Papaverine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Papaverine. Approved Parecoxib The risk or severity of adverse effects can be increased when Enalaprilat is combined with Parecoxib. Approved Pargyline Pargyline may increase the hypotensive activities of Enalaprilat. Approved Parnaparin Parnaparin may increase the hyperkalemic activities of Enalaprilat. Approved Parthenolide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Parthenolide. Investigational Penbutolol Penbutolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Pentobarbital Pentobarbital may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Pentolinium Pentolinium may increase the hypotensive activities of Enalaprilat. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Enalaprilat. Approved, Investigational Perindopril Perindopril may increase the hypotensive activities of Enalaprilat. Approved Pethidine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pethidine. Approved Phenelzine Phenelzine may increase the hypotensive activities of Enalaprilat. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Enalaprilat. Withdrawn Phenobarbital Phenobarbital may increase the hypotensive activities of Enalaprilat. Approved Phenoxybenzamine Phenoxybenzamine may increase the hypotensive activities of Enalaprilat. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Enalaprilat. Withdrawn Phentolamine Phentolamine may increase the hypotensive activities of Enalaprilat. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Phenylbutazone. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pimecrolimus. Approved, Investigational Pimozide The serum concentration of Pimozide can be increased when it is combined with Enalaprilat. Approved Pinacidil Pinacidil may increase the hypotensive activities of Enalaprilat. Withdrawn Pindolol Pindolol may increase the hypotensive activities of Enalaprilat. Approved Pipamperone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pipamperone. Approved Piretanide Piretanide may increase the hypotensive activities of Enalaprilat. Experimental Pirfenidone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pirfenidone. Investigational Pirlindole Pirlindole may increase the hypotensive activities of Enalaprilat. Approved Piroxicam The risk or severity of adverse effects can be increased when Enalaprilat is combined with Piroxicam. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pirprofen. Experimental Pivhydrazine Pivhydrazine may increase the hypotensive activities of Enalaprilat. Withdrawn Polythiazide Polythiazide may increase the hypotensive activities of Enalaprilat. Approved Pramipexole The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pramipexole. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pranoprofen. Experimental Prazosin Prazosin may increase the hypotensive activities of Enalaprilat. Approved Pregabalin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pregabalin. Approved, Illicit, Investigational Primidone Primidone may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Proglumetacin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Propacetamol. Approved Propofol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Propofol. Approved, Investigational, Vet Approved Propranolol Propranolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Proquazone. Experimental Protriptyline The serum concentration of Protriptyline can be increased when it is combined with Enalaprilat. Approved PTC299 The risk or severity of adverse effects can be increased when Enalaprilat is combined with PTC299. Investigational Quetiapine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Quetiapine. Approved Quinapril Quinapril may increase the hypotensive activities of Enalaprilat. Approved, Investigational Quinethazone Quinethazone may increase the hypotensive activities of Enalaprilat. Approved Quinine Quinine may increase the hypotensive activities of Enalaprilat. Approved Ramipril Ramipril may increase the hypotensive activities of Enalaprilat. Approved Rasagiline Rasagiline may increase the hypotensive activities of Enalaprilat. Approved Remifentanil The risk or severity of adverse effects can be increased when Enalaprilat is combined with Remifentanil. Approved Remikiren Remikiren may increase the hypotensive activities of Enalaprilat. Approved Rescinnamine Enalaprilat may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Enalaprilat. Approved Resveratrol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Resveratrol. Experimental, Investigational Reviparin Reviparin may increase the hyperkalemic activities of Enalaprilat. Approved Rilmenidine Rilmenidine may increase the hypotensive activities of Enalaprilat. Investigational Riociguat The serum concentration of Riociguat can be increased when it is combined with Enalaprilat. Approved Risperidone Enalaprilat may increase the hypotensive activities of Risperidone. Approved, Investigational Rituximab Enalaprilat may increase the hypotensive activities of Rituximab. Approved Rofecoxib The risk or severity of adverse effects can be increased when Enalaprilat is combined with Rofecoxib. Investigational, Withdrawn Ropinirole The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropivacaine. Approved Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Enalaprilat. Approved Rotigotine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Rotigotine. Approved Sacubitril The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sacubitril. Approved Safrazine Safrazine may increase the hypotensive activities of Enalaprilat. Withdrawn Salicylamide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Salicylamide. Approved Salicylic acid Salicylic acid may decrease the antihypertensive activities of Enalaprilat. Approved, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Enalaprilat. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Enalaprilat. Investigational Saxagliptin The risk or severity of adverse effects can be increased when Saxagliptin is combined with Enalaprilat. Approved Secobarbital Secobarbital may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Enalaprilat. Approved, Investigational, Vet Approved Selexipag Enalaprilat may increase the hypotensive activities of Selexipag. Approved Semapimod The risk or severity of adverse effects can be increased when Enalaprilat is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when Enalaprilat is combined with Seratrodast. Approved Serrapeptase The risk or severity of adverse effects can be increased when Enalaprilat is combined with Serrapeptase. Investigational Sevoflurane The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sevoflurane. Approved, Vet Approved Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Enalaprilat. Approved, Investigational Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Enalaprilat. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Enalaprilat. Approved Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Enalaprilat. Approved, Investigational Sitagliptin The risk or severity of adverse effects can be increased when Sitagliptin is combined with Enalaprilat. Approved, Investigational Sitaxentan Enalaprilat may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium aurothiomalate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sodium aurothiomalate. Approved Sodium Nitrite The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sodium Nitrite. Approved Sodium phosphate Enalaprilat may increase the nephrotoxic activities of Sodium phosphate. Approved Sotalol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sotalol. Approved Spirapril Spirapril may increase the hypotensive activities of Enalaprilat. Approved Spironolactone Spironolactone may increase the hyperkalemic activities of Enalaprilat. Approved SRT501 The risk or severity of adverse effects can be increased when Enalaprilat is combined with SRT501. Investigational St. John's Wort The metabolism of Enalaprilat can be increased when combined with St. John's Wort. Nutraceutical Streptokinase The risk or severity of adverse effects can be increased when Enalaprilat is combined with Streptokinase. Approved Sufentanil The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sufentanil. Approved, Investigational Sulfasalazine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sulfasalazine. Approved Sulindac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sulindac. Approved Suprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Suprofen. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Suxibuzone. Experimental Synthetic Conjugated Estrogens, A The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Enalaprilat. Approved Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Enalaprilat. Approved, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Enalaprilat. Approved, Investigational Talinolol Enalaprilat may increase the hypotensive activities of Talinolol. Investigational Tamsulosin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tamsulosin. Approved, Investigational Tarenflurbil The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tarenflurbil. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Enalaprilat. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Enalaprilat. Approved, Investigational Temocapril Temocapril may increase the hypotensive activities of Enalaprilat. Experimental, Investigational Temsirolimus The risk or severity of adverse effects can be increased when Enalaprilat is combined with Temsirolimus. Approved Tenidap The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tenidap. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tenoxicam. Approved Tepoxalin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tepoxalin. Vet Approved Terazosin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Terazosin. Approved Teriflunomide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Teriflunomide. Approved Terlipressin Terlipressin may increase the hypotensive activities of Enalaprilat. Approved, Investigational Tetrahydropalmatine Enalaprilat may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Thalidomide. Approved, Investigational, Withdrawn Theodrenaline Enalaprilat may increase the hypotensive activities of Theodrenaline. Investigational Theophylline The serum concentration of Theophylline can be decreased when it is combined with Enalaprilat. Approved Thiamylal Thiamylal may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Thiopental Thiopental may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Thioridazine. Withdrawn Tianeptine The serum concentration of Tianeptine can be increased when it is combined with Enalaprilat. Approved Tiaprofenic acid The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tiaprofenic acid. Approved Tibolone Tibolone may increase the hypotensive activities of Enalaprilat. Approved Ticrynafen Ticrynafen may increase the hypotensive activities of Enalaprilat. Withdrawn Timolol Timolol may increase the hypotensive activities of Enalaprilat. Approved Tinoridine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tinoridine. Investigational Tinzaparin Tinzaparin may increase the hyperkalemic activities of Enalaprilat. Approved Tipranavir The serum concentration of Enalaprilat can be decreased when it is combined with Tipranavir. Approved, Investigational Tizanidine Tizanidine may increase the hypotensive activities of Enalaprilat. Approved Tolazoline Tolazoline may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolcapone. Approved, Withdrawn Tolfenamic Acid The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolfenamic Acid. Approved Tolmetin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolmetin. Approved Tolonidine Enalaprilat may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Enalaprilat. Approved Tolvaptan Tolvaptan may increase the hyperkalemic activities of Enalaprilat. Approved Torasemide Torasemide may increase the hypotensive activities of Enalaprilat. Approved Trandolapril Trandolapril may increase the hypotensive activities of Enalaprilat. Approved Tranilast The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tranilast. Approved, Investigational Trans-2-Phenylcyclopropylamine Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Enalaprilat. Experimental Tranylcypromine Tranylcypromine may increase the hypotensive activities of Enalaprilat. Approved Travoprost Travoprost may increase the hypotensive activities of Enalaprilat. Approved Treprostinil Treprostinil may increase the hypotensive activities of Enalaprilat. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tretinoin. Approved, Investigational, Nutraceutical Triamterene Triamterene may increase the hyperkalemic activities of Enalaprilat. Approved Triazolam The serum concentration of Triazolam can be increased when it is combined with Enalaprilat. Approved Tribenoside The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tribenoside. Experimental Trichlormethiazide Trichlormethiazide may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Enalaprilat. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Enalaprilat. Approved Trimethoprim Trimethoprim may increase the hyperkalemic activities of Enalaprilat. Approved, Vet Approved Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Enalaprilat. Approved Triptolide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Triptolide. Investigational Udenafil Udenafil may increase the antihypertensive activities of Enalaprilat. Approved, Investigational Unoprostone Unoprostone may increase the hypotensive activities of Enalaprilat. Approved Urapidil Urapidil may increase the hypotensive activities of Enalaprilat. Investigational Valdecoxib The risk or severity of adverse effects can be increased when Enalaprilat is combined with Valdecoxib. Investigational, Withdrawn Valproic Acid The serum concentration of Valproic Acid can be decreased when it is combined with Enalaprilat. Approved, Investigational Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Enalaprilat. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Enalaprilat. Approved Verapamil The metabolism of Verapamil can be decreased when combined with Enalaprilat. Approved Vildagliptin The risk or severity of adverse effects can be increased when Vildagliptin is combined with Enalaprilat. Approved, Investigational Vincamine Enalaprilat may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Enalaprilat may increase the hypotensive activities of Vinpocetine. Investigational Xipamide Enalaprilat may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Xylometazoline may increase the hypotensive activities of Enalaprilat. Approved Yohimbine Yohimbine may decrease the antihypertensive activities of Enalaprilat. Approved, Vet Approved Zaltoprofen The risk or severity of adverse effects can be increased when Enalaprilat is combined with Zaltoprofen. Approved Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Enalaprilat. Approved Zileuton The risk or severity of adverse effects can be increased when Enalaprilat is combined with Zileuton. Approved, Investigational, Withdrawn Zofenopril Enalaprilat may increase the hypotensive activities of Zofenopril. Experimental Zomepirac The risk or severity of adverse effects can be increased when Enalaprilat is combined with Zomepirac. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
- Not Available
- General References
- Ulm EH: Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. Drug Metab Rev. 1983;14(1):99-110. [PubMed:6301792]
- Davies RO, Gomez HJ, Irvin JD, Walker JF: An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol. 1984;18 Suppl 2:215S-229S. [PubMed:6099737]
- External Links
- Human Metabolome Database
- HMDB41886
- KEGG Drug
- D03769
- KEGG Compound
- C11720
- ChemSpider
- 4575429
- BindingDB
- 50367254
- ChEBI
- 4786
- ChEMBL
- CHEMBL577
- HET
- EAL
- RxList
- RxList Drug Page
- Wikipedia
- Enalaprilat
- ATC Codes
- Not Available
- AHFS Codes
- Not Available
- PDB Entries
- 1uze / 2x90
- FDA label
- Download (2.99 MB)
- MSDS
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Congestive Cardiomyopathy / Hypertensive 1 4 Completed Basic Science Type 2 Diabetes Mellitus 1 Not Available Completed Not Available Salt-sensitive Hypertension 1 Not Available Completed Health Services Research Idiopathic orthostatic hypotension / Spinal Cord Injuries (SCI) 1 Not Available Completed Treatment CVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages 1 Not Available Completed Treatment Hypertensive / Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Injection Intravenous 1.25 mg/mL Injection Intravenous 2.5 mg/2mL Injection, solution Intravenous 1.25 mg/mL Solution Intravenous 1.25 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.876 mg/mL ALOGPS logP -0.09 ALOGPS logP -1.1 ChemAxon logS -2.6 ALOGPS pKa (Strongest Acidic) 3.13 ChemAxon pKa (Strongest Basic) 7.83 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 106.94 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 90.06 m3·mol-1 ChemAxon Polarizability 35.82 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Dipeptides
- Alternative Parents
- Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides show 8 more
- Substituents
- Alpha-dipeptide / N-acyl-alpha-amino acid / Proline or derivatives / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid / Alpha-amino acid or derivatives / L-alpha-amino acid / N-acylpyrrolidine show 26 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- dipeptide, dicarboxylic acid (CHEBI:4786)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
- Gene Name
- ACE
- Uniprot ID
- P12821
- Uniprot Name
- Angiotensin-converting enzyme
- Molecular Weight
- 149713.675 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Peptide binding
- Specific Function
- This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation.
- Gene Name
- BDKRB1
- Uniprot ID
- P46663
- Uniprot Name
- B1 bradykinin receptor
- Molecular Weight
- 40494.29 Da
References
- Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG: Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem. 2002 May 10;277(19):16847-52. Epub 2002 Mar 5. [PubMed:11880373]
Drug created on November 30, 2015 12:10 / Updated on October 02, 2017 06:16